cMap - NovaResp

Predict and prevent to improve adherance

Our groundbreaking AI algorithms have been designed to deliver lower, more comfortable air pressures. This leads to an improvement in comfort and adherence on conventional CPAP machines. Building on cMAP’s proprietary technology, we are also creating the groundwork to build the next generation of battery-enabled, wearable CPAPs.

Tested in clinical studies

cMAP™ is being developed based on tens of thousands of apneas collected from in-home patient CPAP machines. cMAP™ has been validated in a first-in-human study on current CPAPs in a double-blinded sleep lab study at the QEII hospital in Halifax, Canada.

In a clinical trial, CMAP™ proved to:

Predict respiratory failure at least 2 seconds in advance of an apnea occurring

Predict the type of upcoming apnea (OSA, CSA and hypopnea)

Result in a statistically significant drop in AHI

Lower respiratory effort-related arousals (RERAs)

Lower a patient’s Non-REM heart rate

*Citation: https://pubmed.ncbi.nlm.nih.gov/37030831/

Clinical validation: Gen 1

Q4 2019 – Q3 2020

Observational Study

Completed

Data collection from CPAP users:

Study completed on 70,000 apneas from CPAP users
Over 90% accuracy at least 2 seconds before an apnea

Q4 2021 – Q4 2022

Interventional Study

In Progress

Deploying cMAP™ on real patients:

Integration with commercial CPAPs
Clinicaltrials.gov #CT04873024
11 patients recruited
35% Reduction of AHI

Q1 2023

Interventional Study

Planned

Initiating trials in Germany, USA and Canada:

Health Canada submissions
Preparation for FDA and CE

Aligned incentives that
benefit all stakeholders

MANUFACTURER

Revenue increase for manufacturers due to greater initial acceptance and continued patient use of CPAP machines
Every 5 years new device (device sales)
Increase consumable resupply purchases as more patients use their CPAP machines and for more of the machine’s useful life
Potential for Reduced COGS and greater margins because cMAP technology leads to smaller more compact devices without loss of efficacy.

DME

Increased revenue for Durable Medical Equipment suppliers (DMEs) due to increased saled of machines and consumable resupply
Reduction in labor cost for DMEs because more comfortable use leads to less patient support

Patient

QoL increases
Reduction of co-morbid conditions associated with untreated OSA (heart disease, diabetes,etc)*
12+ months are lifetime users

Dramatically improve
obstructive sleep apnea (OSA)
therapy adherence

cMAP™ is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs

Predict and prevent to improve adherance

Tested in clinical studies

In a clinical trial, CMAP™ proved to:

Clinical validation: Gen 1

Improved comfort leads to
improved adherence

Aligned incentives that
benefit all stakeholders

Want to learn more?

cMAP™ is a patented software which has been designed to be compatible with any Positive Airway Pressure (PAP) machine, including CPAPs

Predict and prevent to improve adherance

Tested in clinical studies

In a clinical trial, CMAP™ proved to:

Clinical validation: Gen 1

Improved comfort leads to improved adherence

Aligned incentives that benefit all stakeholders

Want to learn more?

Improved comfort leads to
improved adherence

Aligned incentives that
benefit all stakeholders